SASCRO Statement on SBRT for Oligo-Metastatic Prostate Cancer
A request was made by a medical scheme to SASCRO on 14 January 2019 for comments on the role of SBRT for oligo-metastatic prostate cancer.
The request did not distinguish between irradiation of the prostate only, in the presence of oligo-metastatic disease or of irradiation of the oligo-metastases themselves. There is also a need to make a distinction between hypo fractionation and SBRT.
